FDA approves Sun's generic Strattera
MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.
Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.
Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.